Short answer
Cytek Biosciences, Inc. (CTKB) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Cytek announced financial results for the quarter ended September 30, 2026.
Cytek Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Cytek announced financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $53.2M, up 2%, with U.S. revenue up 12% and high-end instrument revenue up 11%
- Recurring revenue $19.1M, reaching 36% of trailing-12-month revenue versus 33% previously, improving business visibility
- GAAP gross margin 59%, up 590 basis points, while operating expenses rose 8% to $39.6M
- Net loss widened to $6.1M from $5.5M; adjusted EBITDA declined to $0.7M from $2.5M
- Full-year revenue outlook narrowed to $208M-$211M; cash, restricted cash and securities totaled $256.3M at September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cytek Biosciences, Inc. 8-K filings
Get the next CTKB 8-K as it lands
Follow CTKB for push alerts, or ask the research agent what this filing means.